ANALYSIS OF THE MAIN INDICATORS OF SECONDARY PREVENTION IN PATIENTS WITH CORONARY HEART DISEASE
Abstract
Introduction. The control risk factors of cardiovascular diseases (CVD) in patients with coronary heart disease (CHD) is key to reducing cardiovascular complications and adverse outcomes. Aim of study: to analyze the main indicators of secondary prevention in patients with CHD. Materials and methods. A retrospective analysis of the medical histories of 90 patients with CHD was performed, the age of patients was 63 [59; 70] years. Statistical data processing was carried out using nonparametric statistical methods. Results. An analysis of the main indicators of secondary prevention in patients with CHD showed that the target levels of systolic blood pressure (SBP) were achieved in 80 (89%) of the examined; obesity was diagnosed in 42
(47%), overweight in 37 (42%) patients; data on glycated hemoglobin (HbA1c) were presented in 16 of 44 patients with CHD and carbohydrate metabolism disorder (СMD); in patients with CHD in combination with СMD, HbA1c values of ≤7.5% were in 7 people (of whom patients with DM2 — 4 and with impaired glucose tolerance — 3), whereas its value >7.5% was in 9 patients; dyslipidemia has been associated with CMD, overweight and obesity. Only 20% of CHD patients with СMD and 3% of CHD patients without СMD demonstrated the achievement of low-density lipoprotein cholesterol (LDL) target values against the background of lipid-lowering therapy. Conclusions. The results of the study indicate the presence of difficulties in the implementation of secondary prevention measures in patients with coronary heart disease. It requires not only concerted efforts at the medical and social level, but also the active participation of patients themselves in prevention and health care.
References
Бойцов С.А., Погосова Н.В., Аншелес А.А. и др. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал. 2023; 28(5): 5452. DOI: 10.15829/1560-4071-2023-5452. EDN EUDWYG.
Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А. и др. Ожирение. Consilium Medicum. 2021; 23(4): 311–25. DOI: 10.26442/20751753.2021.4.200832.
Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й выпуск. Сахарный диабет. 2023; 26(2S): 1–157. DOI: 10.14341/DM13042.
Ежов М.В., Кухарчук В.В., Сергиенко И.В. и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023; 28(5): 5471. DOI: 10.15829/1560-4071-2023-5471. EDN YVZOWJ.
Кочегура Т.Н., Акопян Ж.А., Шаронов Г.В. и др. Влияние сопутствующего сахарного диабета 2 типа на количество циркулирующих прогениторных клеток у больных ишемической кардиомиопатией. Сахарный диабет. 2011; 3: 36–43. Доступен по: https://www.dia-endojournals.ru/jour/article/view/6222/3981?locale=ru_RU (дата обращения: 05.04.2024).
Кочегура Т.Н. Молекулярные и клеточные механизмы влияния сопутствующего сахарного диабета 2 типа на течение сердечной недостаточности. Автореф. дис. ... док. мед. наук. Краснодар; 2017.
Погосова Н.В., Оганов Р.Г., Бойцов С.А. и др. Анализ ключевых показателей вторичной профилактики у пациентов с ишемической болезнью сердца в России и Европе по результатам российской части международного многоцентрового исследования EUROASPIRE V. Кардиоваскулярная терапия и профилактика. 2020; 19(6): 2739. DOI: 10.15829/1728-8800-2020-2739.
Badmus O.O., Hillhouse S.A., Anderson C.D. et al. Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways. Clin Sci (Lond). 2022; 136(18): 1347–66. DOI: 10.1042/CS20220572.
Chen S., Yang F., Xu T. et al. Smoking and coronary artery disease risk in patients with diabetes: A Mendelian randomization study. Front. Immunol. 2023; 14: 891947. DOI: 10.3389/fimmu.2023.891947.
Malenica M., Prnjavorac B., Bego T. et al. Effect of Cigarette Smoking on Haematological Parameters in Healthy Population. Med Arch. 2017; 71(2): 132–6. DOI: 10.5455/medarh.2017.71.132-136.
van der Plas A., Antunes M., Pouly S. et al. Meta-analysis of the effects of smoking and smoking cessation on triglyceride levels. Toxicol Rep. 2023; 10: 367–75. DOI: 10.1016/j.toxrep.2023.03.001.
Zlatko Fras, Dimitri P Mikhailidis. Have We Learned all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease) Curr Vasc Pharmacol. 2021; 19(5): 451–68. DOI: 10.2174/1570161118999200727224946.
